Develop Safe, Targeted In Vivo Delivery of RNA, Viral or Gene-Editing Payloads with Clarity in Regulations & Translational Strategy

June 03-05, 2025 | Boston, MA

2025 Agenda
Register
Become a Partner

Advance the Next Frontier of In Vivo Approaches from Research to Clinic

Welcome to the 4th In Vivo Cell Engineering & Gene Editing Summit, the only in vivo dedicated event designed to progress cell and gene therapies to the next frontier.

This summit provides you with exclusive insights into pioneering IND enabling and clinical data, delivery technologies and effective clinical trial designs. Alongside all of this, our speaker faculty will explore regulatory and inter-governmental requirements to accelerate your clinical pipeline.

This year's experts include C-suite executives, VPs and Directors from Myeloid Therapeutics, Ensoma, Capstan Therapeutics, Editas Medicines, AbbVie, Intellia Therapeutics, Umoja BiopharmaΒ and many more!

Biotech and pharma companies are shifting from ex vivo to in vivo therapies due to their improved efficiency, accessibility and cost-effectiveness. With this in mind, this event is a must-attend for those looking to pioneer in this evolving field.

 

Can you afford to miss out?

Event-Guide-Cover-10-02-25
View the Agenda

"In vivo genetic medicines are the future, so having a forum for leaders in the field to explore ways to navigate development to meet the needs of patients is very exciting"
Nicolas Boyle, Chief Executive Officer, Abintus Bio

World-Class Speaker Faculty Includes:

Adrian Bot

Founding Chief Scientific Officer & Executive Vice President - Research & Development

Capstan Therapeutics

Dana Foss

Chief Executive Officer & Co-Founder

Editpep

Daniel Getts

Chief Executive Officer

Myeloid Therapeutics

Gilmore O’Neill

President & Chief Executive Officer

Editas Medicine

Laura Green

Director, Program Management

Umoja Biopharma

Maurits Geerlings

Co-Founder, President & CEO

NanoCell Therapeutics

2025 Speaker Lineup

"The In Vivo Cell Engineering & Gene Editing Summit is a tremendous opportunity to engage with leaders in the field and discuss the latest advances"
Colin Exline, Head of Gene Editing, Primera Therapeutics

Latest Industry News

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT)

Editas Medicine Announces Strategic Transition to In Vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Nona Biosciences Partners with Alaya.bio for CAR-T Therapy

Capstan Heats Up β€˜In Vivo’ Cell Therapy Chase with $175M Fundraise

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

View the Full Agenda for More Information on:

        • 21+ In Vivo C-Suite Executives, VPs and Directors
        • 20+ Exclusive Sessions
        • 2 Interactive Deep-Dive Workshops
        • 8+ Hours of Industry Networking

Β  Β  Β  Β  Β  Β  Β  Β  Β  & Much More!

Explore Here
Event-Guide-Cover-10-02-25
2025 Agenda
Register
Become a Partner